nodes	percent_of_prediction	percent_of_DWPC	metapath
L-Carnitine—MPO—urinary bladder cancer	0.344	1	CbGaD
L-Carnitine—SLC22A16—Doxorubicin—urinary bladder cancer	0.186	0.414	CbGbCtD
L-Carnitine—MPO—Carboplatin—urinary bladder cancer	0.056	0.125	CbGbCtD
L-Carnitine—XDH—Carboplatin—urinary bladder cancer	0.056	0.125	CbGbCtD
L-Carnitine—MPO—Cisplatin—urinary bladder cancer	0.0478	0.106	CbGbCtD
L-Carnitine—XDH—Cisplatin—urinary bladder cancer	0.0478	0.106	CbGbCtD
L-Carnitine—XDH—Doxorubicin—urinary bladder cancer	0.0321	0.0713	CbGbCtD
L-Carnitine—SLCO1B1—Methotrexate—urinary bladder cancer	0.0123	0.0275	CbGbCtD
L-Carnitine—SLC22A8—Methotrexate—urinary bladder cancer	0.0114	0.0254	CbGbCtD
L-Carnitine—SLC25A29—prostate gland—urinary bladder cancer	0.00323	0.0412	CbGeAlD
L-Carnitine—CROT—prostate gland—urinary bladder cancer	0.00297	0.0378	CbGeAlD
L-Carnitine—SLC22A16—renal system—urinary bladder cancer	0.0028	0.0356	CbGeAlD
L-Carnitine—SLC25A20—prostate gland—urinary bladder cancer	0.00258	0.0328	CbGeAlD
L-Carnitine—CRAT—prostate gland—urinary bladder cancer	0.0025	0.0319	CbGeAlD
L-Carnitine—SLC22A16—female reproductive system—urinary bladder cancer	0.00224	0.0285	CbGeAlD
L-Carnitine—SLC25A20—seminal vesicle—urinary bladder cancer	0.00218	0.0278	CbGeAlD
L-Carnitine—SLC22A8—urine—urinary bladder cancer	0.00213	0.0271	CbGeAlD
L-Carnitine—CRAT—seminal vesicle—urinary bladder cancer	0.00212	0.027	CbGeAlD
L-Carnitine—CROT—smooth muscle tissue—urinary bladder cancer	0.0021	0.0267	CbGeAlD
L-Carnitine—CPT1A—prostate gland—urinary bladder cancer	0.00203	0.0258	CbGeAlD
L-Carnitine—CPT2—prostate gland—urinary bladder cancer	0.00193	0.0245	CbGeAlD
L-Carnitine—CRAT—smooth muscle tissue—urinary bladder cancer	0.00177	0.0226	CbGeAlD
L-Carnitine—SLC25A29—female reproductive system—urinary bladder cancer	0.00177	0.0225	CbGeAlD
L-Carnitine—SLC25A20—renal system—urinary bladder cancer	0.00176	0.0224	CbGeAlD
L-Carnitine—SLC25A20—urethra—urinary bladder cancer	0.00173	0.022	CbGeAlD
L-Carnitine—CRAT—renal system—urinary bladder cancer	0.00171	0.0217	CbGeAlD
L-Carnitine—CRAT—urethra—urinary bladder cancer	0.00168	0.0213	CbGeAlD
L-Carnitine—CPT2—seminal vesicle—urinary bladder cancer	0.00163	0.0207	CbGeAlD
L-Carnitine—CROT—female reproductive system—urinary bladder cancer	0.00162	0.0206	CbGeAlD
L-Carnitine—XDH—prostate gland—urinary bladder cancer	0.0015	0.0191	CbGeAlD
L-Carnitine—CROT—vagina—urinary bladder cancer	0.00146	0.0186	CbGeAlD
L-Carnitine—SLC25A20—female reproductive system—urinary bladder cancer	0.00141	0.0179	CbGeAlD
L-Carnitine—CPT1A—renal system—urinary bladder cancer	0.00138	0.0176	CbGeAlD
L-Carnitine—CRAT—female reproductive system—urinary bladder cancer	0.00137	0.0174	CbGeAlD
L-Carnitine—CPT2—renal system—urinary bladder cancer	0.00131	0.0167	CbGeAlD
L-Carnitine—CPT2—urethra—urinary bladder cancer	0.00129	0.0164	CbGeAlD
L-Carnitine—SLC25A20—vagina—urinary bladder cancer	0.00127	0.0162	CbGeAlD
L-Carnitine—CRAT—vagina—urinary bladder cancer	0.00124	0.0157	CbGeAlD
L-Carnitine—CES1—prostate gland—urinary bladder cancer	0.00114	0.0146	CbGeAlD
L-Carnitine—CPT1A—female reproductive system—urinary bladder cancer	0.00111	0.0141	CbGeAlD
L-Carnitine—CPT2—female reproductive system—urinary bladder cancer	0.00105	0.0134	CbGeAlD
L-Carnitine—SLC25A29—lymph node—urinary bladder cancer	0.00103	0.0131	CbGeAlD
L-Carnitine—XDH—renal system—urinary bladder cancer	0.00102	0.013	CbGeAlD
L-Carnitine—CPT1A—vagina—urinary bladder cancer	0.001	0.0128	CbGeAlD
L-Carnitine—CPT2—vagina—urinary bladder cancer	0.000951	0.0121	CbGeAlD
L-Carnitine—CROT—lymph node—urinary bladder cancer	0.000947	0.0121	CbGeAlD
L-Carnitine—SLC22A4—prostate gland—urinary bladder cancer	0.000872	0.0111	CbGeAlD
L-Carnitine—SLC25A20—lymph node—urinary bladder cancer	0.000824	0.0105	CbGeAlD
L-Carnitine—XDH—female reproductive system—urinary bladder cancer	0.000819	0.0104	CbGeAlD
L-Carnitine—CRAT—lymph node—urinary bladder cancer	0.0008	0.0102	CbGeAlD
L-Carnitine—SLC22A8—prostate gland—urinary bladder cancer	0.000764	0.00972	CbGeAlD
L-Carnitine—XDH—vagina—urinary bladder cancer	0.000741	0.00943	CbGeAlD
L-Carnitine—SLC22A4—seminal vesicle—urinary bladder cancer	0.000738	0.00939	CbGeAlD
L-Carnitine—MPO—epithelium—urinary bladder cancer	0.000702	0.00893	CbGeAlD
L-Carnitine—SLCO1B1—renal system—urinary bladder cancer	0.00067	0.00853	CbGeAlD
L-Carnitine—MPO—renal system—urinary bladder cancer	0.000651	0.00829	CbGeAlD
L-Carnitine—CPT1A—lymph node—urinary bladder cancer	0.000648	0.00825	CbGeAlD
L-Carnitine—CES1—female reproductive system—urinary bladder cancer	0.000624	0.00795	CbGeAlD
L-Carnitine—CPT2—lymph node—urinary bladder cancer	0.000615	0.00783	CbGeAlD
L-Carnitine—SLC22A4—renal system—urinary bladder cancer	0.000595	0.00757	CbGeAlD
L-Carnitine—SLC22A5—prostate gland—urinary bladder cancer	0.000577	0.00735	CbGeAlD
L-Carnitine—SLCO1B1—female reproductive system—urinary bladder cancer	0.000536	0.00683	CbGeAlD
L-Carnitine—SLC22A8—renal system—urinary bladder cancer	0.00052	0.00662	CbGeAlD
L-Carnitine—SLC22A5—seminal vesicle—urinary bladder cancer	0.000488	0.00621	CbGeAlD
L-Carnitine—SLC22A4—female reproductive system—urinary bladder cancer	0.000476	0.00606	CbGeAlD
L-Carnitine—SLC22A4—vagina—urinary bladder cancer	0.000431	0.00548	CbGeAlD
L-Carnitine—SLC22A5—renal system—urinary bladder cancer	0.000393	0.00501	CbGeAlD
L-Carnitine—SLC22A5—urethra—urinary bladder cancer	0.000386	0.00492	CbGeAlD
L-Carnitine—CES1—lymph node—urinary bladder cancer	0.000365	0.00465	CbGeAlD
L-Carnitine—SLC22A5—female reproductive system—urinary bladder cancer	0.000315	0.00401	CbGeAlD
L-Carnitine—MPO—lymph node—urinary bladder cancer	0.000305	0.00388	CbGeAlD
L-Carnitine—SLC22A5—vagina—urinary bladder cancer	0.000285	0.00363	CbGeAlD
L-Carnitine—SLC22A4—lymph node—urinary bladder cancer	0.000279	0.00355	CbGeAlD
L-Carnitine—SLC22A5—lymph node—urinary bladder cancer	0.000184	0.00235	CbGeAlD
L-Carnitine—Gastrointestinal pain—Thiotepa—urinary bladder cancer	0.000165	0.00243	CcSEcCtD
L-Carnitine—Anxiety—Cisplatin—urinary bladder cancer	0.000164	0.00243	CcSEcCtD
L-Carnitine—Anaemia—Etoposide—urinary bladder cancer	0.000164	0.00242	CcSEcCtD
L-Carnitine—Tachycardia—Fluorouracil—urinary bladder cancer	0.000163	0.0024	CcSEcCtD
L-Carnitine—Anorexia—Gemcitabine—urinary bladder cancer	0.000162	0.00239	CcSEcCtD
L-Carnitine—Vertigo—Etoposide—urinary bladder cancer	0.000159	0.00235	CcSEcCtD
L-Carnitine—Body temperature increased—Thiotepa—urinary bladder cancer	0.000159	0.00235	CcSEcCtD
L-Carnitine—Abdominal pain—Thiotepa—urinary bladder cancer	0.000159	0.00235	CcSEcCtD
L-Carnitine—Anorexia—Fluorouracil—urinary bladder cancer	0.000159	0.00235	CcSEcCtD
L-Carnitine—Hypotension—Gemcitabine—urinary bladder cancer	0.000158	0.00234	CcSEcCtD
L-Carnitine—Infection—Cisplatin—urinary bladder cancer	0.000157	0.00232	CcSEcCtD
L-Carnitine—Hypotension—Fluorouracil—urinary bladder cancer	0.000156	0.0023	CcSEcCtD
L-Carnitine—Cough—Etoposide—urinary bladder cancer	0.000155	0.00229	CcSEcCtD
L-Carnitine—Musculoskeletal discomfort—Gemcitabine—urinary bladder cancer	0.000154	0.00228	CcSEcCtD
L-Carnitine—Tachycardia—Cisplatin—urinary bladder cancer	0.000154	0.00228	CcSEcCtD
L-Carnitine—Convulsion—Etoposide—urinary bladder cancer	0.000154	0.00227	CcSEcCtD
L-Carnitine—Insomnia—Gemcitabine—urinary bladder cancer	0.000153	0.00226	CcSEcCtD
L-Carnitine—Hypertension—Etoposide—urinary bladder cancer	0.000153	0.00226	CcSEcCtD
L-Carnitine—Paraesthesia—Gemcitabine—urinary bladder cancer	0.000152	0.00225	CcSEcCtD
L-Carnitine—Musculoskeletal discomfort—Fluorouracil—urinary bladder cancer	0.000152	0.00224	CcSEcCtD
L-Carnitine—Dyspnoea—Gemcitabine—urinary bladder cancer	0.000151	0.00223	CcSEcCtD
L-Carnitine—Chest pain—Etoposide—urinary bladder cancer	0.000151	0.00223	CcSEcCtD
L-Carnitine—Insomnia—Fluorouracil—urinary bladder cancer	0.000151	0.00223	CcSEcCtD
L-Carnitine—Anorexia—Cisplatin—urinary bladder cancer	0.000151	0.00222	CcSEcCtD
L-Carnitine—Paraesthesia—Fluorouracil—urinary bladder cancer	0.00015	0.00221	CcSEcCtD
L-Carnitine—Dyspnoea—Fluorouracil—urinary bladder cancer	0.000149	0.00219	CcSEcCtD
L-Carnitine—Hypersensitivity—Thiotepa—urinary bladder cancer	0.000148	0.00219	CcSEcCtD
L-Carnitine—Hypotension—Cisplatin—urinary bladder cancer	0.000148	0.00218	CcSEcCtD
L-Carnitine—Decreased appetite—Gemcitabine—urinary bladder cancer	0.000147	0.00218	CcSEcCtD
L-Carnitine—Dyspepsia—Fluorouracil—urinary bladder cancer	0.000147	0.00217	CcSEcCtD
L-Carnitine—Gastrointestinal disorder—Gemcitabine—urinary bladder cancer	0.000146	0.00216	CcSEcCtD
L-Carnitine—Gastritis—Epirubicin—urinary bladder cancer	0.000146	0.00216	CcSEcCtD
L-Carnitine—Muscular weakness—Epirubicin—urinary bladder cancer	0.000146	0.00215	CcSEcCtD
L-Carnitine—Pain—Gemcitabine—urinary bladder cancer	0.000145	0.00214	CcSEcCtD
L-Carnitine—Constipation—Gemcitabine—urinary bladder cancer	0.000145	0.00214	CcSEcCtD
L-Carnitine—Decreased appetite—Fluorouracil—urinary bladder cancer	0.000145	0.00214	CcSEcCtD
L-Carnitine—Asthenia—Thiotepa—urinary bladder cancer	0.000145	0.00214	CcSEcCtD
L-Carnitine—Musculoskeletal discomfort—Cisplatin—urinary bladder cancer	0.000144	0.00213	CcSEcCtD
L-Carnitine—Gastrointestinal disorder—Fluorouracil—urinary bladder cancer	0.000144	0.00213	CcSEcCtD
L-Carnitine—Infection—Etoposide—urinary bladder cancer	0.000144	0.00212	CcSEcCtD
L-Carnitine—Influenza—Epirubicin—urinary bladder cancer	0.000143	0.00211	CcSEcCtD
L-Carnitine—Pruritus—Thiotepa—urinary bladder cancer	0.000143	0.00211	CcSEcCtD
L-Carnitine—Pain—Fluorouracil—urinary bladder cancer	0.000143	0.0021	CcSEcCtD
L-Carnitine—Paraesthesia—Cisplatin—urinary bladder cancer	0.000142	0.0021	CcSEcCtD
L-Carnitine—Tachycardia—Etoposide—urinary bladder cancer	0.000141	0.00209	CcSEcCtD
L-Carnitine—Dyspnoea—Cisplatin—urinary bladder cancer	0.000141	0.00208	CcSEcCtD
L-Carnitine—Anorexia—Etoposide—urinary bladder cancer	0.000138	0.00204	CcSEcCtD
L-Carnitine—Diarrhoea—Thiotepa—urinary bladder cancer	0.000138	0.00204	CcSEcCtD
L-Carnitine—Decreased appetite—Cisplatin—urinary bladder cancer	0.000137	0.00203	CcSEcCtD
L-Carnitine—Bronchitis—Epirubicin—urinary bladder cancer	0.000137	0.00203	CcSEcCtD
L-Carnitine—Gastrointestinal disorder—Cisplatin—urinary bladder cancer	0.000136	0.00201	CcSEcCtD
L-Carnitine—Depression—Methotrexate—urinary bladder cancer	0.000136	0.002	CcSEcCtD
L-Carnitine—Hypotension—Etoposide—urinary bladder cancer	0.000135	0.002	CcSEcCtD
L-Carnitine—Gastritis—Doxorubicin—urinary bladder cancer	0.000135	0.002	CcSEcCtD
L-Carnitine—Pain—Cisplatin—urinary bladder cancer	0.000135	0.002	CcSEcCtD
L-Carnitine—Muscular weakness—Doxorubicin—urinary bladder cancer	0.000135	0.00199	CcSEcCtD
L-Carnitine—Body temperature increased—Gemcitabine—urinary bladder cancer	0.000134	0.00198	CcSEcCtD
L-Carnitine—Renal failure—Methotrexate—urinary bladder cancer	0.000134	0.00197	CcSEcCtD
L-Carnitine—Dizziness—Thiotepa—urinary bladder cancer	0.000133	0.00197	CcSEcCtD
L-Carnitine—CPT2—Metabolism—UGT2B7—urinary bladder cancer	0.000133	0.00219	CbGpPWpGaD
L-Carnitine—Influenza—Doxorubicin—urinary bladder cancer	0.000132	0.00195	CcSEcCtD
L-Carnitine—Body temperature increased—Fluorouracil—urinary bladder cancer	0.000132	0.00195	CcSEcCtD
L-Carnitine—CRAT—Metabolism of lipids and lipoproteins—GPX1—urinary bladder cancer	0.000131	0.00216	CbGpPWpGaD
L-Carnitine—SLC25A20—Metabolism of lipids and lipoproteins—GPX1—urinary bladder cancer	0.000131	0.00216	CbGpPWpGaD
L-Carnitine—Paraesthesia—Etoposide—urinary bladder cancer	0.00013	0.00192	CcSEcCtD
L-Carnitine—Weight increased—Epirubicin—urinary bladder cancer	0.00013	0.00192	CcSEcCtD
L-Carnitine—Weight decreased—Epirubicin—urinary bladder cancer	0.000129	0.00191	CcSEcCtD
L-Carnitine—Dyspnoea—Etoposide—urinary bladder cancer	0.000129	0.00191	CcSEcCtD
L-Carnitine—MPO—C-MYB transcription factor network—CDKN2A—urinary bladder cancer	0.000129	0.00213	CbGpPWpGaD
L-Carnitine—Vomiting—Thiotepa—urinary bladder cancer	0.000128	0.00189	CcSEcCtD
L-Carnitine—Rash—Thiotepa—urinary bladder cancer	0.000127	0.00188	CcSEcCtD
L-Carnitine—Bronchitis—Doxorubicin—urinary bladder cancer	0.000127	0.00188	CcSEcCtD
L-Carnitine—Dermatitis—Thiotepa—urinary bladder cancer	0.000127	0.00187	CcSEcCtD
L-Carnitine—CES1—E2F transcription factor network—CDKN1A—urinary bladder cancer	0.000127	0.0021	CbGpPWpGaD
L-Carnitine—Headache—Thiotepa—urinary bladder cancer	0.000126	0.00186	CcSEcCtD
L-Carnitine—CPT1A—Circadian rythm related genes—FAS—urinary bladder cancer	0.000126	0.00208	CbGpPWpGaD
L-Carnitine—Decreased appetite—Etoposide—urinary bladder cancer	0.000126	0.00186	CcSEcCtD
L-Carnitine—CROT—Metabolism—RRM2—urinary bladder cancer	0.000125	0.00207	CbGpPWpGaD
L-Carnitine—Renal failure—Epirubicin—urinary bladder cancer	0.000125	0.00185	CcSEcCtD
L-Carnitine—Gastrointestinal disorder—Etoposide—urinary bladder cancer	0.000125	0.00185	CcSEcCtD
L-Carnitine—Body temperature increased—Cisplatin—urinary bladder cancer	0.000125	0.00184	CcSEcCtD
L-Carnitine—Pain—Etoposide—urinary bladder cancer	0.000124	0.00183	CcSEcCtD
L-Carnitine—Constipation—Etoposide—urinary bladder cancer	0.000124	0.00183	CcSEcCtD
L-Carnitine—Urinary tract infection—Epirubicin—urinary bladder cancer	0.000124	0.00183	CcSEcCtD
L-Carnitine—SLC25A20—Metabolism—NAT2—urinary bladder cancer	0.000123	0.00204	CbGpPWpGaD
L-Carnitine—CRAT—Metabolism—NAT2—urinary bladder cancer	0.000123	0.00204	CbGpPWpGaD
L-Carnitine—Hypersensitivity—Fluorouracil—urinary bladder cancer	0.000123	0.00181	CcSEcCtD
L-Carnitine—Haemoglobin—Methotrexate—urinary bladder cancer	0.000123	0.00181	CcSEcCtD
L-Carnitine—Haemorrhage—Methotrexate—urinary bladder cancer	0.000122	0.0018	CcSEcCtD
L-Carnitine—Asthenia—Gemcitabine—urinary bladder cancer	0.000122	0.0018	CcSEcCtD
L-Carnitine—MPO—Vitamin B12 Metabolism—TNF—urinary bladder cancer	0.000121	0.002	CbGpPWpGaD
L-Carnitine—Pharyngitis—Methotrexate—urinary bladder cancer	0.000121	0.00179	CcSEcCtD
L-Carnitine—CES1—E2F transcription factor network—EP300—urinary bladder cancer	0.000121	0.00199	CbGpPWpGaD
L-Carnitine—MPO—C-MYB transcription factor network—PTGS2—urinary bladder cancer	0.000121	0.00199	CbGpPWpGaD
L-Carnitine—Weight increased—Doxorubicin—urinary bladder cancer	0.00012	0.00177	CcSEcCtD
L-Carnitine—Pruritus—Gemcitabine—urinary bladder cancer	0.00012	0.00177	CcSEcCtD
L-Carnitine—Nausea—Thiotepa—urinary bladder cancer	0.00012	0.00177	CcSEcCtD
L-Carnitine—Weight decreased—Doxorubicin—urinary bladder cancer	0.000119	0.00176	CcSEcCtD
L-Carnitine—CPT2—Metabolism—CYP4B1—urinary bladder cancer	0.000119	0.00197	CbGpPWpGaD
L-Carnitine—Sinusitis—Epirubicin—urinary bladder cancer	0.000119	0.00176	CcSEcCtD
L-Carnitine—CPT1A—SIDS Susceptibility Pathways—CREBBP—urinary bladder cancer	0.000118	0.00196	CbGpPWpGaD
L-Carnitine—Gastrointestinal pain—Etoposide—urinary bladder cancer	0.000118	0.00175	CcSEcCtD
L-Carnitine—Pruritus—Fluorouracil—urinary bladder cancer	0.000118	0.00174	CcSEcCtD
L-Carnitine—Hypersensitivity—Cisplatin—urinary bladder cancer	0.000116	0.00172	CcSEcCtD
L-Carnitine—MPO—Selenium Micronutrient Network—PTGS2—urinary bladder cancer	0.000116	0.00192	CbGpPWpGaD
L-Carnitine—Diarrhoea—Gemcitabine—urinary bladder cancer	0.000116	0.00171	CcSEcCtD
L-Carnitine—CROT—Metabolism—HPGDS—urinary bladder cancer	0.000116	0.00192	CbGpPWpGaD
L-Carnitine—CROT—Metabolism—ENO2—urinary bladder cancer	0.000116	0.00192	CbGpPWpGaD
L-Carnitine—Renal failure—Doxorubicin—urinary bladder cancer	0.000116	0.00171	CcSEcCtD
L-Carnitine—CROT—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	0.000115	0.0019	CbGpPWpGaD
L-Carnitine—Haemoglobin—Epirubicin—urinary bladder cancer	0.000115	0.0017	CcSEcCtD
L-Carnitine—Rhinitis—Epirubicin—urinary bladder cancer	0.000114	0.00169	CcSEcCtD
L-Carnitine—Body temperature increased—Etoposide—urinary bladder cancer	0.000114	0.00169	CcSEcCtD
L-Carnitine—Abdominal pain—Etoposide—urinary bladder cancer	0.000114	0.00169	CcSEcCtD
L-Carnitine—Urinary tract infection—Doxorubicin—urinary bladder cancer	0.000114	0.00169	CcSEcCtD
L-Carnitine—Haemorrhage—Epirubicin—urinary bladder cancer	0.000114	0.00169	CcSEcCtD
L-Carnitine—Eye disorder—Methotrexate—urinary bladder cancer	0.000114	0.00168	CcSEcCtD
L-Carnitine—Diarrhoea—Fluorouracil—urinary bladder cancer	0.000114	0.00168	CcSEcCtD
L-Carnitine—Asthenia—Cisplatin—urinary bladder cancer	0.000113	0.00167	CcSEcCtD
L-Carnitine—Pharyngitis—Epirubicin—urinary bladder cancer	0.000113	0.00167	CcSEcCtD
L-Carnitine—CPT2—Metabolism—SLC19A1—urinary bladder cancer	0.000113	0.00186	CbGpPWpGaD
L-Carnitine—Oedema peripheral—Epirubicin—urinary bladder cancer	0.000112	0.00166	CcSEcCtD
L-Carnitine—CROT—Metabolism—GSTT1—urinary bladder cancer	0.000112	0.00186	CbGpPWpGaD
L-Carnitine—CPT1A—AMPK Signaling—TP53—urinary bladder cancer	0.000111	0.00183	CbGpPWpGaD
L-Carnitine—CPT1A—Circadian rythm related genes—CDK4—urinary bladder cancer	0.000111	0.00183	CbGpPWpGaD
L-Carnitine—CROT—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	0.000111	0.00183	CbGpPWpGaD
L-Carnitine—Angiopathy—Methotrexate—urinary bladder cancer	0.000111	0.00164	CcSEcCtD
L-Carnitine—Sinusitis—Doxorubicin—urinary bladder cancer	0.00011	0.00163	CcSEcCtD
L-Carnitine—Dizziness—Fluorouracil—urinary bladder cancer	0.00011	0.00163	CcSEcCtD
L-Carnitine—CPT1A—Fatty acid, triacylglycerol, and ketone body metabolism—PPARG—urinary bladder cancer	0.00011	0.00182	CbGpPWpGaD
L-Carnitine—CPT2—Metabolism—PRSS3—urinary bladder cancer	0.00011	0.00182	CbGpPWpGaD
L-Carnitine—SLC22A5—Transmembrane transport of small molecules—SLC14A2—urinary bladder cancer	0.000109	0.0018	CbGpPWpGaD
L-Carnitine—MPO—C-MYB transcription factor network—CCND1—urinary bladder cancer	0.000109	0.0018	CbGpPWpGaD
L-Carnitine—Diarrhoea—Cisplatin—urinary bladder cancer	0.000108	0.0016	CcSEcCtD
L-Carnitine—Vomiting—Gemcitabine—urinary bladder cancer	0.000108	0.00159	CcSEcCtD
L-Carnitine—Rash—Gemcitabine—urinary bladder cancer	0.000107	0.00158	CcSEcCtD
L-Carnitine—Dermatitis—Gemcitabine—urinary bladder cancer	0.000107	0.00158	CcSEcCtD
L-Carnitine—Eye disorder—Epirubicin—urinary bladder cancer	0.000107	0.00158	CcSEcCtD
L-Carnitine—CPT1A—PPARA activates gene expression—EP300—urinary bladder cancer	0.000107	0.00176	CbGpPWpGaD
L-Carnitine—Hypersensitivity—Etoposide—urinary bladder cancer	0.000107	0.00158	CcSEcCtD
L-Carnitine—SLC25A20—Metabolism—RRM2—urinary bladder cancer	0.000106	0.00176	CbGpPWpGaD
L-Carnitine—CRAT—Metabolism—RRM2—urinary bladder cancer	0.000106	0.00176	CbGpPWpGaD
L-Carnitine—Haemoglobin—Doxorubicin—urinary bladder cancer	0.000106	0.00157	CcSEcCtD
L-Carnitine—Headache—Gemcitabine—urinary bladder cancer	0.000106	0.00157	CcSEcCtD
L-Carnitine—CPT1A—Metabolism—GSTZ1—urinary bladder cancer	0.000106	0.00175	CbGpPWpGaD
L-Carnitine—Vomiting—Fluorouracil—urinary bladder cancer	0.000106	0.00157	CcSEcCtD
L-Carnitine—Rhinitis—Doxorubicin—urinary bladder cancer	0.000106	0.00156	CcSEcCtD
L-Carnitine—Haemorrhage—Doxorubicin—urinary bladder cancer	0.000106	0.00156	CcSEcCtD
L-Carnitine—CPT1A—Fatty acid, triacylglycerol, and ketone body metabolism—CREBBP—urinary bladder cancer	0.000106	0.00174	CbGpPWpGaD
L-Carnitine—MPO—C-MYB transcription factor network—CDKN1A—urinary bladder cancer	0.000105	0.00174	CbGpPWpGaD
L-Carnitine—CES1—E2F transcription factor network—MYC—urinary bladder cancer	0.000105	0.00174	CbGpPWpGaD
L-Carnitine—Rash—Fluorouracil—urinary bladder cancer	0.000105	0.00155	CcSEcCtD
L-Carnitine—Dermatitis—Fluorouracil—urinary bladder cancer	0.000105	0.00155	CcSEcCtD
L-Carnitine—Pharyngitis—Doxorubicin—urinary bladder cancer	0.000105	0.00155	CcSEcCtD
L-Carnitine—SLC22A4—Transmembrane transport of small molecules—AQP3—urinary bladder cancer	0.000105	0.00173	CbGpPWpGaD
L-Carnitine—Headache—Fluorouracil—urinary bladder cancer	0.000104	0.00154	CcSEcCtD
L-Carnitine—CPT1A—Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)—EP300—urinary bladder cancer	0.000104	0.00172	CbGpPWpGaD
L-Carnitine—Oedema peripheral—Doxorubicin—urinary bladder cancer	0.000104	0.00154	CcSEcCtD
L-Carnitine—Dysgeusia—Methotrexate—urinary bladder cancer	0.000104	0.00154	CcSEcCtD
L-Carnitine—Asthenia—Etoposide—urinary bladder cancer	0.000104	0.00153	CcSEcCtD
L-Carnitine—CPT2—Fatty acid, triacylglycerol, and ketone body metabolism—EP300—urinary bladder cancer	0.000104	0.00171	CbGpPWpGaD
L-Carnitine—Angiopathy—Epirubicin—urinary bladder cancer	0.000104	0.00153	CcSEcCtD
L-Carnitine—Back pain—Methotrexate—urinary bladder cancer	0.000103	0.00152	CcSEcCtD
L-Carnitine—Pruritus—Etoposide—urinary bladder cancer	0.000102	0.00151	CcSEcCtD
L-Carnitine—Arrhythmia—Epirubicin—urinary bladder cancer	0.000102	0.00151	CcSEcCtD
L-Carnitine—XDH—Selenium Micronutrient Network—PTGS2—urinary bladder cancer	0.000102	0.00168	CbGpPWpGaD
L-Carnitine—Nausea—Gemcitabine—urinary bladder cancer	0.000101	0.00149	CcSEcCtD
L-Carnitine—CPT1A—Circadian rythm related genes—PPARG—urinary bladder cancer	0.000101	0.00166	CbGpPWpGaD
L-Carnitine—CPT1A—Metabolism—GSTO2—urinary bladder cancer	0.000101	0.00166	CbGpPWpGaD
L-Carnitine—CPT1A—Metabolism—NAT1—urinary bladder cancer	0.000101	0.00166	CbGpPWpGaD
L-Carnitine—Vomiting—Cisplatin—urinary bladder cancer	0.0001	0.00148	CcSEcCtD
L-Carnitine—MPO—C-MYB transcription factor network—EP300—urinary bladder cancer	0.0001	0.00166	CbGpPWpGaD
L-Carnitine—Rash—Cisplatin—urinary bladder cancer	9.96e-05	0.00147	CcSEcCtD
L-Carnitine—Dermatitis—Cisplatin—urinary bladder cancer	9.95e-05	0.00147	CcSEcCtD
L-Carnitine—Diarrhoea—Etoposide—urinary bladder cancer	9.9e-05	0.00146	CcSEcCtD
L-Carnitine—Nausea—Fluorouracil—urinary bladder cancer	9.9e-05	0.00146	CcSEcCtD
L-Carnitine—CPT1A—Metabolism of lipids and lipoproteins—HPGDS—urinary bladder cancer	9.89e-05	0.00163	CbGpPWpGaD
L-Carnitine—Eye disorder—Doxorubicin—urinary bladder cancer	9.87e-05	0.00146	CcSEcCtD
L-Carnitine—MPO—Folate Metabolism—TNF—urinary bladder cancer	9.87e-05	0.00163	CbGpPWpGaD
L-Carnitine—SLC25A20—Metabolism—HPGDS—urinary bladder cancer	9.86e-05	0.00163	CbGpPWpGaD
L-Carnitine—CRAT—Metabolism—HPGDS—urinary bladder cancer	9.86e-05	0.00163	CbGpPWpGaD
L-Carnitine—CRAT—Metabolism—ENO2—urinary bladder cancer	9.86e-05	0.00163	CbGpPWpGaD
L-Carnitine—SLC25A20—Metabolism—ENO2—urinary bladder cancer	9.86e-05	0.00163	CbGpPWpGaD
L-Carnitine—SLC22A8—Transmembrane transport of small molecules—SLC14A2—urinary bladder cancer	9.85e-05	0.00163	CbGpPWpGaD
L-Carnitine—Anaemia—Methotrexate—urinary bladder cancer	9.82e-05	0.00145	CcSEcCtD
L-Carnitine—CRAT—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	9.8e-05	0.00162	CbGpPWpGaD
L-Carnitine—SLC25A20—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	9.8e-05	0.00162	CbGpPWpGaD
L-Carnitine—Dysgeusia—Epirubicin—urinary bladder cancer	9.73e-05	0.00144	CcSEcCtD
L-Carnitine—Back pain—Epirubicin—urinary bladder cancer	9.62e-05	0.00142	CcSEcCtD
L-Carnitine—Angiopathy—Doxorubicin—urinary bladder cancer	9.59e-05	0.00142	CcSEcCtD
L-Carnitine—Dizziness—Etoposide—urinary bladder cancer	9.57e-05	0.00141	CcSEcCtD
L-Carnitine—SLC25A20—Metabolism—GSTT1—urinary bladder cancer	9.56e-05	0.00158	CbGpPWpGaD
L-Carnitine—CRAT—Metabolism—GSTT1—urinary bladder cancer	9.56e-05	0.00158	CbGpPWpGaD
L-Carnitine—Muscle spasms—Epirubicin—urinary bladder cancer	9.56e-05	0.00141	CcSEcCtD
L-Carnitine—Vertigo—Methotrexate—urinary bladder cancer	9.54e-05	0.00141	CcSEcCtD
L-Carnitine—Arrhythmia—Doxorubicin—urinary bladder cancer	9.44e-05	0.00139	CcSEcCtD
L-Carnitine—SLC25A20—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	9.41e-05	0.00156	CbGpPWpGaD
L-Carnitine—CRAT—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	9.41e-05	0.00156	CbGpPWpGaD
L-Carnitine—CPT1A—SIDS Susceptibility Pathways—CXCL8—urinary bladder cancer	9.4e-05	0.00155	CbGpPWpGaD
L-Carnitine—Nausea—Cisplatin—urinary bladder cancer	9.38e-05	0.00139	CcSEcCtD
L-Carnitine—CROT—Metabolism—NQO1—urinary bladder cancer	9.35e-05	0.00154	CbGpPWpGaD
L-Carnitine—Cough—Methotrexate—urinary bladder cancer	9.27e-05	0.00137	CcSEcCtD
L-Carnitine—Convulsion—Methotrexate—urinary bladder cancer	9.2e-05	0.00136	CcSEcCtD
L-Carnitine—Vomiting—Etoposide—urinary bladder cancer	9.2e-05	0.00136	CcSEcCtD
L-Carnitine—CPT1A—Metabolism—UGT2B7—urinary bladder cancer	9.19e-05	0.00152	CbGpPWpGaD
L-Carnitine—Anaemia—Epirubicin—urinary bladder cancer	9.19e-05	0.00136	CcSEcCtD
L-Carnitine—Rash—Etoposide—urinary bladder cancer	9.13e-05	0.00135	CcSEcCtD
L-Carnitine—Dermatitis—Etoposide—urinary bladder cancer	9.12e-05	0.00135	CcSEcCtD
L-Carnitine—Headache—Etoposide—urinary bladder cancer	9.07e-05	0.00134	CcSEcCtD
L-Carnitine—CROT—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	9.07e-05	0.0015	CbGpPWpGaD
L-Carnitine—Chest pain—Methotrexate—urinary bladder cancer	9.04e-05	0.00134	CcSEcCtD
L-Carnitine—Myalgia—Methotrexate—urinary bladder cancer	9.04e-05	0.00134	CcSEcCtD
L-Carnitine—Dysgeusia—Doxorubicin—urinary bladder cancer	9.01e-05	0.00133	CcSEcCtD
L-Carnitine—Vertigo—Epirubicin—urinary bladder cancer	8.93e-05	0.00132	CcSEcCtD
L-Carnitine—Back pain—Doxorubicin—urinary bladder cancer	8.9e-05	0.00131	CcSEcCtD
L-Carnitine—Muscle spasms—Doxorubicin—urinary bladder cancer	8.84e-05	0.00131	CcSEcCtD
L-Carnitine—CPT2—Metabolism of lipids and lipoproteins—NCOR1—urinary bladder cancer	8.81e-05	0.00146	CbGpPWpGaD
L-Carnitine—CPT2—Metabolism—TYMP—urinary bladder cancer	8.79e-05	0.00145	CbGpPWpGaD
L-Carnitine—Palpitations—Epirubicin—urinary bladder cancer	8.78e-05	0.0013	CcSEcCtD
L-Carnitine—MPO—C-MYB transcription factor network—MYC—urinary bladder cancer	8.74e-05	0.00144	CbGpPWpGaD
L-Carnitine—MPO—Folate Metabolism—TP53—urinary bladder cancer	8.7e-05	0.00144	CbGpPWpGaD
L-Carnitine—Cough—Epirubicin—urinary bladder cancer	8.67e-05	0.00128	CcSEcCtD
L-Carnitine—Convulsion—Epirubicin—urinary bladder cancer	8.61e-05	0.00127	CcSEcCtD
L-Carnitine—Infection—Methotrexate—urinary bladder cancer	8.61e-05	0.00127	CcSEcCtD
L-Carnitine—Nausea—Etoposide—urinary bladder cancer	8.6e-05	0.00127	CcSEcCtD
L-Carnitine—Hypertension—Epirubicin—urinary bladder cancer	8.58e-05	0.00127	CcSEcCtD
L-Carnitine—SLC22A4—Transmembrane transport of small molecules—TRPV1—urinary bladder cancer	8.54e-05	0.00141	CbGpPWpGaD
L-Carnitine—Anaemia—Doxorubicin—urinary bladder cancer	8.5e-05	0.00126	CcSEcCtD
L-Carnitine—Chest pain—Epirubicin—urinary bladder cancer	8.46e-05	0.00125	CcSEcCtD
L-Carnitine—Myalgia—Epirubicin—urinary bladder cancer	8.46e-05	0.00125	CcSEcCtD
L-Carnitine—CPT2—Metabolism of lipids and lipoproteins—GPX1—urinary bladder cancer	8.44e-05	0.00139	CbGpPWpGaD
L-Carnitine—Anxiety—Epirubicin—urinary bladder cancer	8.43e-05	0.00125	CcSEcCtD
L-Carnitine—CPT1A—Metabolism—CYP4B1—urinary bladder cancer	8.28e-05	0.00137	CbGpPWpGaD
L-Carnitine—Vertigo—Doxorubicin—urinary bladder cancer	8.26e-05	0.00122	CcSEcCtD
L-Carnitine—Anorexia—Methotrexate—urinary bladder cancer	8.26e-05	0.00122	CcSEcCtD
L-Carnitine—Palpitations—Doxorubicin—urinary bladder cancer	8.13e-05	0.0012	CcSEcCtD
L-Carnitine—Hypotension—Methotrexate—urinary bladder cancer	8.1e-05	0.0012	CcSEcCtD
L-Carnitine—MPO—C-MYB transcription factor network—KRAS—urinary bladder cancer	8.07e-05	0.00133	CbGpPWpGaD
L-Carnitine—CPT1A—SIDS Susceptibility Pathways—EP300—urinary bladder cancer	8.06e-05	0.00133	CbGpPWpGaD
L-Carnitine—Infection—Epirubicin—urinary bladder cancer	8.06e-05	0.00119	CcSEcCtD
L-Carnitine—Cough—Doxorubicin—urinary bladder cancer	8.03e-05	0.00119	CcSEcCtD
L-Carnitine—Convulsion—Doxorubicin—urinary bladder cancer	7.97e-05	0.00118	CcSEcCtD
L-Carnitine—CRAT—Metabolism—NQO1—urinary bladder cancer	7.95e-05	0.00131	CbGpPWpGaD
L-Carnitine—CPT2—Metabolism—NAT2—urinary bladder cancer	7.95e-05	0.00131	CbGpPWpGaD
L-Carnitine—SLC25A20—Metabolism—NQO1—urinary bladder cancer	7.95e-05	0.00131	CbGpPWpGaD
L-Carnitine—Hypertension—Doxorubicin—urinary bladder cancer	7.94e-05	0.00117	CcSEcCtD
L-Carnitine—Tachycardia—Epirubicin—urinary bladder cancer	7.92e-05	0.00117	CcSEcCtD
L-Carnitine—CROT—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	7.91e-05	0.00131	CbGpPWpGaD
L-Carnitine—Musculoskeletal discomfort—Methotrexate—urinary bladder cancer	7.9e-05	0.00117	CcSEcCtD
L-Carnitine—SLC22A5—Transmembrane transport of small molecules—AQP3—urinary bladder cancer	7.88e-05	0.0013	CbGpPWpGaD
L-Carnitine—MPO—Selenium Micronutrient Network—TNF—urinary bladder cancer	7.84e-05	0.0013	CbGpPWpGaD
L-Carnitine—Insomnia—Methotrexate—urinary bladder cancer	7.84e-05	0.00116	CcSEcCtD
L-Carnitine—Chest pain—Doxorubicin—urinary bladder cancer	7.83e-05	0.00116	CcSEcCtD
L-Carnitine—Myalgia—Doxorubicin—urinary bladder cancer	7.83e-05	0.00116	CcSEcCtD
L-Carnitine—CPT1A—Metabolism—SLC19A1—urinary bladder cancer	7.82e-05	0.00129	CbGpPWpGaD
L-Carnitine—Anxiety—Doxorubicin—urinary bladder cancer	7.8e-05	0.00115	CcSEcCtD
L-Carnitine—CROT—Metabolism—GSTP1—urinary bladder cancer	7.79e-05	0.00129	CbGpPWpGaD
L-Carnitine—Paraesthesia—Methotrexate—urinary bladder cancer	7.78e-05	0.00115	CcSEcCtD
L-Carnitine—Anorexia—Epirubicin—urinary bladder cancer	7.73e-05	0.00114	CcSEcCtD
L-Carnitine—Dyspnoea—Methotrexate—urinary bladder cancer	7.73e-05	0.00114	CcSEcCtD
L-Carnitine—CRAT—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	7.71e-05	0.00127	CbGpPWpGaD
L-Carnitine—SLC25A20—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	7.71e-05	0.00127	CbGpPWpGaD
L-Carnitine—Dyspepsia—Methotrexate—urinary bladder cancer	7.63e-05	0.00113	CcSEcCtD
L-Carnitine—CPT1A—Metabolism—PRSS3—urinary bladder cancer	7.62e-05	0.00126	CbGpPWpGaD
L-Carnitine—Hypotension—Epirubicin—urinary bladder cancer	7.58e-05	0.00112	CcSEcCtD
L-Carnitine—CROT—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	7.54e-05	0.00125	CbGpPWpGaD
L-Carnitine—Decreased appetite—Methotrexate—urinary bladder cancer	7.54e-05	0.00111	CcSEcCtD
L-Carnitine—Gastrointestinal disorder—Methotrexate—urinary bladder cancer	7.48e-05	0.00111	CcSEcCtD
L-Carnitine—SLCO1B1—Transmembrane transport of small molecules—SLC14A2—urinary bladder cancer	7.48e-05	0.00124	CbGpPWpGaD
L-Carnitine—Infection—Doxorubicin—urinary bladder cancer	7.46e-05	0.0011	CcSEcCtD
L-Carnitine—Pain—Methotrexate—urinary bladder cancer	7.41e-05	0.00109	CcSEcCtD
L-Carnitine—Musculoskeletal discomfort—Epirubicin—urinary bladder cancer	7.39e-05	0.00109	CcSEcCtD
L-Carnitine—Insomnia—Epirubicin—urinary bladder cancer	7.34e-05	0.00108	CcSEcCtD
L-Carnitine—Tachycardia—Doxorubicin—urinary bladder cancer	7.33e-05	0.00108	CcSEcCtD
L-Carnitine—SLC22A16—Transmembrane transport of small molecules—CREBBP—urinary bladder cancer	7.3e-05	0.00121	CbGpPWpGaD
L-Carnitine—Paraesthesia—Epirubicin—urinary bladder cancer	7.29e-05	0.00108	CcSEcCtD
L-Carnitine—CROT—Metabolism—TYMS—urinary bladder cancer	7.25e-05	0.0012	CbGpPWpGaD
L-Carnitine—Dyspnoea—Epirubicin—urinary bladder cancer	7.23e-05	0.00107	CcSEcCtD
L-Carnitine—CPT1A—Fatty acid, triacylglycerol, and ketone body metabolism—EP300—urinary bladder cancer	7.19e-05	0.00119	CbGpPWpGaD
L-Carnitine—CROT—Metabolism—NCOR1—urinary bladder cancer	7.16e-05	0.00118	CbGpPWpGaD
L-Carnitine—CROT—Metabolism—GSTM1—urinary bladder cancer	7.16e-05	0.00118	CbGpPWpGaD
L-Carnitine—Anorexia—Doxorubicin—urinary bladder cancer	7.16e-05	0.00106	CcSEcCtD
L-Carnitine—Dyspepsia—Epirubicin—urinary bladder cancer	7.14e-05	0.00105	CcSEcCtD
L-Carnitine—SLC22A8—Transmembrane transport of small molecules—AQP3—urinary bladder cancer	7.12e-05	0.00118	CbGpPWpGaD
L-Carnitine—Gastrointestinal pain—Methotrexate—urinary bladder cancer	7.09e-05	0.00105	CcSEcCtD
L-Carnitine—Decreased appetite—Epirubicin—urinary bladder cancer	7.05e-05	0.00104	CcSEcCtD
L-Carnitine—XDH—Metabolism—GSTZ1—urinary bladder cancer	7.02e-05	0.00116	CbGpPWpGaD
L-Carnitine—Hypotension—Doxorubicin—urinary bladder cancer	7.01e-05	0.00104	CcSEcCtD
L-Carnitine—Gastrointestinal disorder—Epirubicin—urinary bladder cancer	7e-05	0.00103	CcSEcCtD
L-Carnitine—Pain—Epirubicin—urinary bladder cancer	6.94e-05	0.00102	CcSEcCtD
L-Carnitine—Constipation—Epirubicin—urinary bladder cancer	6.94e-05	0.00102	CcSEcCtD
L-Carnitine—CPT1A—Circadian rythm related genes—PTEN—urinary bladder cancer	6.9e-05	0.00114	CbGpPWpGaD
L-Carnitine—MPO—C-MYB transcription factor network—HRAS—urinary bladder cancer	6.86e-05	0.00113	CbGpPWpGaD
L-Carnitine—CPT2—Metabolism—RRM2—urinary bladder cancer	6.86e-05	0.00113	CbGpPWpGaD
L-Carnitine—CROT—Metabolism—GPX1—urinary bladder cancer	6.86e-05	0.00113	CbGpPWpGaD
L-Carnitine—XDH—Selenium Micronutrient Network—TNF—urinary bladder cancer	6.86e-05	0.00113	CbGpPWpGaD
L-Carnitine—Abdominal pain—Methotrexate—urinary bladder cancer	6.85e-05	0.00101	CcSEcCtD
L-Carnitine—Body temperature increased—Methotrexate—urinary bladder cancer	6.85e-05	0.00101	CcSEcCtD
L-Carnitine—Musculoskeletal discomfort—Doxorubicin—urinary bladder cancer	6.84e-05	0.00101	CcSEcCtD
L-Carnitine—Insomnia—Doxorubicin—urinary bladder cancer	6.79e-05	0.001	CcSEcCtD
L-Carnitine—Paraesthesia—Doxorubicin—urinary bladder cancer	6.74e-05	0.000996	CcSEcCtD
L-Carnitine—CROT—Metabolism—ERCC2—urinary bladder cancer	6.73e-05	0.00111	CbGpPWpGaD
L-Carnitine—CRAT—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	6.72e-05	0.00111	CbGpPWpGaD
L-Carnitine—SLC25A20—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	6.72e-05	0.00111	CbGpPWpGaD
L-Carnitine—Dyspnoea—Doxorubicin—urinary bladder cancer	6.69e-05	0.000989	CcSEcCtD
L-Carnitine—XDH—Metabolism—GSTO2—urinary bladder cancer	6.66e-05	0.0011	CbGpPWpGaD
L-Carnitine—XDH—Metabolism—NAT1—urinary bladder cancer	6.66e-05	0.0011	CbGpPWpGaD
L-Carnitine—Gastrointestinal pain—Epirubicin—urinary bladder cancer	6.63e-05	0.00098	CcSEcCtD
L-Carnitine—CRAT—Metabolism—GSTP1—urinary bladder cancer	6.63e-05	0.00109	CbGpPWpGaD
L-Carnitine—SLC25A20—Metabolism—GSTP1—urinary bladder cancer	6.63e-05	0.00109	CbGpPWpGaD
L-Carnitine—Dyspepsia—Doxorubicin—urinary bladder cancer	6.61e-05	0.000976	CcSEcCtD
L-Carnitine—CPT1A—Circadian rythm related genes—EP300—urinary bladder cancer	6.58e-05	0.00109	CbGpPWpGaD
L-Carnitine—CPT1A—SIDS Susceptibility Pathways—TNF—urinary bladder cancer	6.55e-05	0.00108	CbGpPWpGaD
L-Carnitine—Decreased appetite—Doxorubicin—urinary bladder cancer	6.53e-05	0.000964	CcSEcCtD
L-Carnitine—Gastrointestinal disorder—Doxorubicin—urinary bladder cancer	6.48e-05	0.000957	CcSEcCtD
L-Carnitine—SLCO1B1—Metabolism of lipids and lipoproteins—CYP4B1—urinary bladder cancer	6.48e-05	0.00107	CbGpPWpGaD
L-Carnitine—SLC22A5—Transmembrane transport of small molecules—TRPV1—urinary bladder cancer	6.42e-05	0.00106	CbGpPWpGaD
L-Carnitine—Pain—Doxorubicin—urinary bladder cancer	6.42e-05	0.000948	CcSEcCtD
L-Carnitine—Constipation—Doxorubicin—urinary bladder cancer	6.42e-05	0.000948	CcSEcCtD
L-Carnitine—Body temperature increased—Epirubicin—urinary bladder cancer	6.41e-05	0.000947	CcSEcCtD
L-Carnitine—Abdominal pain—Epirubicin—urinary bladder cancer	6.41e-05	0.000947	CcSEcCtD
L-Carnitine—CRAT—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	6.41e-05	0.00106	CbGpPWpGaD
L-Carnitine—SLC25A20—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	6.41e-05	0.00106	CbGpPWpGaD
L-Carnitine—Hypersensitivity—Methotrexate—urinary bladder cancer	6.39e-05	0.000943	CcSEcCtD
L-Carnitine—CPT2—Metabolism—ENO2—urinary bladder cancer	6.35e-05	0.00105	CbGpPWpGaD
L-Carnitine—CPT2—Metabolism—HPGDS—urinary bladder cancer	6.35e-05	0.00105	CbGpPWpGaD
L-Carnitine—CROT—Metabolism—MTHFR—urinary bladder cancer	6.33e-05	0.00105	CbGpPWpGaD
L-Carnitine—CPT2—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	6.32e-05	0.00104	CbGpPWpGaD
L-Carnitine—Asthenia—Methotrexate—urinary bladder cancer	6.22e-05	0.000919	CcSEcCtD
L-Carnitine—CPT2—Metabolism—GSTT1—urinary bladder cancer	6.16e-05	0.00102	CbGpPWpGaD
L-Carnitine—CRAT—Metabolism—TYMS—urinary bladder cancer	6.16e-05	0.00102	CbGpPWpGaD
L-Carnitine—SLC25A20—Metabolism—TYMS—urinary bladder cancer	6.16e-05	0.00102	CbGpPWpGaD
L-Carnitine—Gastrointestinal pain—Doxorubicin—urinary bladder cancer	6.14e-05	0.000907	CcSEcCtD
L-Carnitine—Pruritus—Methotrexate—urinary bladder cancer	6.13e-05	0.000906	CcSEcCtD
L-Carnitine—CPT1A—Metabolism of lipids and lipoproteins—NCOR1—urinary bladder cancer	6.11e-05	0.00101	CbGpPWpGaD
L-Carnitine—SLC25A20—Metabolism—GSTM1—urinary bladder cancer	6.09e-05	0.00101	CbGpPWpGaD
L-Carnitine—CPT1A—Metabolism—TYMP—urinary bladder cancer	6.09e-05	0.00101	CbGpPWpGaD
L-Carnitine—SLC25A20—Metabolism—NCOR1—urinary bladder cancer	6.09e-05	0.00101	CbGpPWpGaD
L-Carnitine—CRAT—Metabolism—NCOR1—urinary bladder cancer	6.09e-05	0.00101	CbGpPWpGaD
L-Carnitine—XDH—Metabolism—UGT2B7—urinary bladder cancer	6.09e-05	0.00101	CbGpPWpGaD
L-Carnitine—CRAT—Metabolism—GSTM1—urinary bladder cancer	6.09e-05	0.00101	CbGpPWpGaD
L-Carnitine—CPT2—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	6.07e-05	0.001	CbGpPWpGaD
L-Carnitine—Hypersensitivity—Epirubicin—urinary bladder cancer	5.98e-05	0.000883	CcSEcCtD
L-Carnitine—Abdominal pain—Doxorubicin—urinary bladder cancer	5.93e-05	0.000877	CcSEcCtD
L-Carnitine—Body temperature increased—Doxorubicin—urinary bladder cancer	5.93e-05	0.000877	CcSEcCtD
L-Carnitine—Diarrhoea—Methotrexate—urinary bladder cancer	5.93e-05	0.000876	CcSEcCtD
L-Carnitine—CPT1A—Metabolism of lipids and lipoproteins—GPX1—urinary bladder cancer	5.85e-05	0.000966	CbGpPWpGaD
L-Carnitine—CRAT—Metabolism—GPX1—urinary bladder cancer	5.83e-05	0.000963	CbGpPWpGaD
L-Carnitine—SLC25A20—Metabolism—GPX1—urinary bladder cancer	5.83e-05	0.000963	CbGpPWpGaD
L-Carnitine—Asthenia—Epirubicin—urinary bladder cancer	5.82e-05	0.00086	CcSEcCtD
L-Carnitine—SLC22A8—Transmembrane transport of small molecules—TRPV1—urinary bladder cancer	5.81e-05	0.000959	CbGpPWpGaD
L-Carnitine—SLC22A4—Transmembrane transport of small molecules—TFRC—urinary bladder cancer	5.77e-05	0.000953	CbGpPWpGaD
L-Carnitine—Pruritus—Epirubicin—urinary bladder cancer	5.74e-05	0.000848	CcSEcCtD
L-Carnitine—Dizziness—Methotrexate—urinary bladder cancer	5.73e-05	0.000847	CcSEcCtD
L-Carnitine—SLC25A20—Metabolism—ERCC2—urinary bladder cancer	5.73e-05	0.000946	CbGpPWpGaD
L-Carnitine—CRAT—Metabolism—ERCC2—urinary bladder cancer	5.73e-05	0.000946	CbGpPWpGaD
L-Carnitine—Diarrhoea—Epirubicin—urinary bladder cancer	5.55e-05	0.00082	CcSEcCtD
L-Carnitine—Hypersensitivity—Doxorubicin—urinary bladder cancer	5.53e-05	0.000817	CcSEcCtD
L-Carnitine—Vomiting—Methotrexate—urinary bladder cancer	5.51e-05	0.000814	CcSEcCtD
L-Carnitine—CPT1A—Metabolism—NAT2—urinary bladder cancer	5.51e-05	0.00091	CbGpPWpGaD
L-Carnitine—XDH—Metabolism—CYP4B1—urinary bladder cancer	5.48e-05	0.000906	CbGpPWpGaD
L-Carnitine—Rash—Methotrexate—urinary bladder cancer	5.47e-05	0.000807	CcSEcCtD
L-Carnitine—Dermatitis—Methotrexate—urinary bladder cancer	5.46e-05	0.000807	CcSEcCtD
L-Carnitine—Headache—Methotrexate—urinary bladder cancer	5.43e-05	0.000802	CcSEcCtD
L-Carnitine—SLCO1B1—Transmembrane transport of small molecules—AQP3—urinary bladder cancer	5.41e-05	0.000894	CbGpPWpGaD
L-Carnitine—Asthenia—Doxorubicin—urinary bladder cancer	5.39e-05	0.000796	CcSEcCtD
L-Carnitine—SLC25A20—Metabolism—MTHFR—urinary bladder cancer	5.38e-05	0.000889	CbGpPWpGaD
L-Carnitine—CRAT—Metabolism—MTHFR—urinary bladder cancer	5.38e-05	0.000889	CbGpPWpGaD
L-Carnitine—Dizziness—Epirubicin—urinary bladder cancer	5.37e-05	0.000792	CcSEcCtD
L-Carnitine—Pruritus—Doxorubicin—urinary bladder cancer	5.31e-05	0.000784	CcSEcCtD
L-Carnitine—XDH—Metabolism—SLC19A1—urinary bladder cancer	5.18e-05	0.000855	CbGpPWpGaD
L-Carnitine—Vomiting—Epirubicin—urinary bladder cancer	5.16e-05	0.000762	CcSEcCtD
L-Carnitine—Nausea—Methotrexate—urinary bladder cancer	5.15e-05	0.000761	CcSEcCtD
L-Carnitine—Diarrhoea—Doxorubicin—urinary bladder cancer	5.14e-05	0.000759	CcSEcCtD
L-Carnitine—CROT—Metabolism—PPARG—urinary bladder cancer	5.13e-05	0.000848	CbGpPWpGaD
L-Carnitine—CPT2—Metabolism—NQO1—urinary bladder cancer	5.12e-05	0.000846	CbGpPWpGaD
L-Carnitine—Rash—Epirubicin—urinary bladder cancer	5.12e-05	0.000756	CcSEcCtD
L-Carnitine—Dermatitis—Epirubicin—urinary bladder cancer	5.11e-05	0.000755	CcSEcCtD
L-Carnitine—Headache—Epirubicin—urinary bladder cancer	5.08e-05	0.000751	CcSEcCtD
L-Carnitine—XDH—Metabolism—PRSS3—urinary bladder cancer	5.05e-05	0.000834	CbGpPWpGaD
L-Carnitine—CPT2—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	4.97e-05	0.000821	CbGpPWpGaD
L-Carnitine—Dizziness—Doxorubicin—urinary bladder cancer	4.96e-05	0.000733	CcSEcCtD
L-Carnitine—CROT—Metabolism—CREBBP—urinary bladder cancer	4.93e-05	0.000815	CbGpPWpGaD
L-Carnitine—Nausea—Epirubicin—urinary bladder cancer	4.82e-05	0.000712	CcSEcCtD
L-Carnitine—Vomiting—Doxorubicin—urinary bladder cancer	4.77e-05	0.000705	CcSEcCtD
L-Carnitine—CPT1A—Metabolism—RRM2—urinary bladder cancer	4.75e-05	0.000785	CbGpPWpGaD
L-Carnitine—Rash—Doxorubicin—urinary bladder cancer	4.73e-05	0.000699	CcSEcCtD
L-Carnitine—Dermatitis—Doxorubicin—urinary bladder cancer	4.73e-05	0.000698	CcSEcCtD
L-Carnitine—CPT1A—Circadian rythm related genes—TP53—urinary bladder cancer	4.71e-05	0.000778	CbGpPWpGaD
L-Carnitine—Headache—Doxorubicin—urinary bladder cancer	4.7e-05	0.000695	CcSEcCtD
L-Carnitine—Nausea—Doxorubicin—urinary bladder cancer	4.46e-05	0.000659	CcSEcCtD
L-Carnitine—SLCO1B1—Transmembrane transport of small molecules—TRPV1—urinary bladder cancer	4.41e-05	0.000729	CbGpPWpGaD
L-Carnitine—CPT1A—Metabolism—ENO2—urinary bladder cancer	4.4e-05	0.000727	CbGpPWpGaD
L-Carnitine—CPT1A—Metabolism—HPGDS—urinary bladder cancer	4.4e-05	0.000727	CbGpPWpGaD
L-Carnitine—CPT1A—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	4.38e-05	0.000723	CbGpPWpGaD
L-Carnitine—CRAT—Metabolism—PPARG—urinary bladder cancer	4.36e-05	0.000721	CbGpPWpGaD
L-Carnitine—SLC25A20—Metabolism—PPARG—urinary bladder cancer	4.36e-05	0.000721	CbGpPWpGaD
L-Carnitine—SLC22A5—Transmembrane transport of small molecules—TFRC—urinary bladder cancer	4.34e-05	0.000717	CbGpPWpGaD
L-Carnitine—CPT2—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	4.33e-05	0.000716	CbGpPWpGaD
L-Carnitine—CPT1A—Metabolism—GSTT1—urinary bladder cancer	4.27e-05	0.000706	CbGpPWpGaD
L-Carnitine—CPT2—Metabolism—GSTP1—urinary bladder cancer	4.27e-05	0.000706	CbGpPWpGaD
L-Carnitine—CPT1A—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	4.21e-05	0.000695	CbGpPWpGaD
L-Carnitine—SLC25A20—Metabolism—CREBBP—urinary bladder cancer	4.19e-05	0.000693	CbGpPWpGaD
L-Carnitine—CRAT—Metabolism—CREBBP—urinary bladder cancer	4.19e-05	0.000693	CbGpPWpGaD
L-Carnitine—CPT2—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	4.13e-05	0.000683	CbGpPWpGaD
L-Carnitine—CROT—Metabolism—PTGS2—urinary bladder cancer	4.04e-05	0.000667	CbGpPWpGaD
L-Carnitine—XDH—Metabolism—TYMP—urinary bladder cancer	4.03e-05	0.000666	CbGpPWpGaD
L-Carnitine—CPT2—Metabolism—TYMS—urinary bladder cancer	3.97e-05	0.000656	CbGpPWpGaD
L-Carnitine—CPT2—Metabolism—NCOR1—urinary bladder cancer	3.92e-05	0.000648	CbGpPWpGaD
L-Carnitine—CPT2—Metabolism—GSTM1—urinary bladder cancer	3.92e-05	0.000648	CbGpPWpGaD
L-Carnitine—SLC22A8—Transmembrane transport of small molecules—TFRC—urinary bladder cancer	3.92e-05	0.000648	CbGpPWpGaD
L-Carnitine—CPT2—Metabolism—GPX1—urinary bladder cancer	3.76e-05	0.000621	CbGpPWpGaD
L-Carnitine—SLCO1B1—Metabolism—GSTZ1—urinary bladder cancer	3.7e-05	0.000611	CbGpPWpGaD
L-Carnitine—CPT2—Metabolism—ERCC2—urinary bladder cancer	3.69e-05	0.00061	CbGpPWpGaD
L-Carnitine—XDH—Metabolism—NAT2—urinary bladder cancer	3.65e-05	0.000603	CbGpPWpGaD
L-Carnitine—CPT1A—Metabolism—NQO1—urinary bladder cancer	3.55e-05	0.000586	CbGpPWpGaD
L-Carnitine—CROT—Metabolism—PTEN—urinary bladder cancer	3.52e-05	0.000582	CbGpPWpGaD
L-Carnitine—SLCO1B1—Metabolism—GSTO2—urinary bladder cancer	3.5e-05	0.000579	CbGpPWpGaD
L-Carnitine—SLCO1B1—Metabolism—NAT1—urinary bladder cancer	3.5e-05	0.000579	CbGpPWpGaD
L-Carnitine—CPT2—Metabolism—MTHFR—urinary bladder cancer	3.47e-05	0.000573	CbGpPWpGaD
L-Carnitine—SLCO1B1—Metabolism of lipids and lipoproteins—HPGDS—urinary bladder cancer	3.45e-05	0.000569	CbGpPWpGaD
L-Carnitine—CPT1A—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	3.44e-05	0.000569	CbGpPWpGaD
L-Carnitine—CRAT—Metabolism—PTGS2—urinary bladder cancer	3.43e-05	0.000567	CbGpPWpGaD
L-Carnitine—SLC25A20—Metabolism—PTGS2—urinary bladder cancer	3.43e-05	0.000567	CbGpPWpGaD
L-Carnitine—CROT—Metabolism—EP300—urinary bladder cancer	3.36e-05	0.000555	CbGpPWpGaD
L-Carnitine—SLCO1B1—Metabolism—UGT2B7—urinary bladder cancer	3.21e-05	0.00053	CbGpPWpGaD
L-Carnitine—XDH—Metabolism—RRM2—urinary bladder cancer	3.15e-05	0.00052	CbGpPWpGaD
L-Carnitine—CPT1A—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	3e-05	0.000496	CbGpPWpGaD
L-Carnitine—SLC25A20—Metabolism—PTEN—urinary bladder cancer	2.99e-05	0.000495	CbGpPWpGaD
L-Carnitine—CRAT—Metabolism—PTEN—urinary bladder cancer	2.99e-05	0.000495	CbGpPWpGaD
L-Carnitine—SLCO1B1—Transmembrane transport of small molecules—TFRC—urinary bladder cancer	2.98e-05	0.000492	CbGpPWpGaD
L-Carnitine—CPT1A—Metabolism—GSTP1—urinary bladder cancer	2.96e-05	0.000489	CbGpPWpGaD
L-Carnitine—XDH—Metabolism—HPGDS—urinary bladder cancer	2.92e-05	0.000482	CbGpPWpGaD
L-Carnitine—XDH—Metabolism—ENO2—urinary bladder cancer	2.92e-05	0.000482	CbGpPWpGaD
L-Carnitine—SLCO1B1—Metabolism—CYP4B1—urinary bladder cancer	2.89e-05	0.000477	CbGpPWpGaD
L-Carnitine—CPT1A—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	2.86e-05	0.000473	CbGpPWpGaD
L-Carnitine—SLC25A20—Metabolism—EP300—urinary bladder cancer	2.86e-05	0.000472	CbGpPWpGaD
L-Carnitine—CRAT—Metabolism—EP300—urinary bladder cancer	2.86e-05	0.000472	CbGpPWpGaD
L-Carnitine—XDH—Metabolism—GSTT1—urinary bladder cancer	2.83e-05	0.000467	CbGpPWpGaD
L-Carnitine—CPT2—Metabolism—PPARG—urinary bladder cancer	2.81e-05	0.000465	CbGpPWpGaD
L-Carnitine—CPT1A—Metabolism—TYMS—urinary bladder cancer	2.75e-05	0.000455	CbGpPWpGaD
L-Carnitine—SLCO1B1—Metabolism—SLC19A1—urinary bladder cancer	2.73e-05	0.00045	CbGpPWpGaD
L-Carnitine—CPT1A—Metabolism—NCOR1—urinary bladder cancer	2.72e-05	0.000449	CbGpPWpGaD
L-Carnitine—CPT1A—Metabolism—GSTM1—urinary bladder cancer	2.72e-05	0.000449	CbGpPWpGaD
L-Carnitine—CPT2—Metabolism—CREBBP—urinary bladder cancer	2.7e-05	0.000446	CbGpPWpGaD
L-Carnitine—SLC22A4—Transmembrane transport of small molecules—CREBBP—urinary bladder cancer	2.7e-05	0.000446	CbGpPWpGaD
L-Carnitine—SLCO1B1—Metabolism—PRSS3—urinary bladder cancer	2.66e-05	0.000439	CbGpPWpGaD
L-Carnitine—CPT1A—Metabolism—GPX1—urinary bladder cancer	2.61e-05	0.00043	CbGpPWpGaD
L-Carnitine—CPT1A—Metabolism—ERCC2—urinary bladder cancer	2.56e-05	0.000423	CbGpPWpGaD
L-Carnitine—CPT1A—Metabolism—MTHFR—urinary bladder cancer	2.4e-05	0.000397	CbGpPWpGaD
L-Carnitine—XDH—Metabolism—NQO1—urinary bladder cancer	2.35e-05	0.000388	CbGpPWpGaD
L-Carnitine—CPT2—Metabolism—PTGS2—urinary bladder cancer	2.21e-05	0.000366	CbGpPWpGaD
L-Carnitine—SLCO1B1—Metabolism of lipids and lipoproteins—NCOR1—urinary bladder cancer	2.13e-05	0.000352	CbGpPWpGaD
L-Carnitine—SLCO1B1—Metabolism—TYMP—urinary bladder cancer	2.12e-05	0.000351	CbGpPWpGaD
L-Carnitine—SLCO1B1—Metabolism of lipids and lipoproteins—GPX1—urinary bladder cancer	2.04e-05	0.000337	CbGpPWpGaD
L-Carnitine—SLC22A5—Transmembrane transport of small molecules—CREBBP—urinary bladder cancer	2.03e-05	0.000335	CbGpPWpGaD
L-Carnitine—XDH—Metabolism—GSTP1—urinary bladder cancer	1.96e-05	0.000324	CbGpPWpGaD
L-Carnitine—CPT1A—Metabolism—PPARG—urinary bladder cancer	1.95e-05	0.000322	CbGpPWpGaD
L-Carnitine—CPT2—Metabolism—PTEN—urinary bladder cancer	1.93e-05	0.000319	CbGpPWpGaD
L-Carnitine—SLCO1B1—Metabolism—NAT2—urinary bladder cancer	1.92e-05	0.000317	CbGpPWpGaD
L-Carnitine—CPT1A—Metabolism—CREBBP—urinary bladder cancer	1.87e-05	0.000309	CbGpPWpGaD
L-Carnitine—CPT2—Metabolism—EP300—urinary bladder cancer	1.84e-05	0.000304	CbGpPWpGaD
L-Carnitine—SLC22A8—Transmembrane transport of small molecules—CREBBP—urinary bladder cancer	1.84e-05	0.000303	CbGpPWpGaD
L-Carnitine—XDH—Metabolism—TYMS—urinary bladder cancer	1.82e-05	0.000301	CbGpPWpGaD
L-Carnitine—XDH—Metabolism—NCOR1—urinary bladder cancer	1.8e-05	0.000298	CbGpPWpGaD
L-Carnitine—XDH—Metabolism—GSTM1—urinary bladder cancer	1.8e-05	0.000298	CbGpPWpGaD
L-Carnitine—XDH—Metabolism—GPX1—urinary bladder cancer	1.73e-05	0.000285	CbGpPWpGaD
L-Carnitine—XDH—Metabolism—ERCC2—urinary bladder cancer	1.69e-05	0.00028	CbGpPWpGaD
L-Carnitine—SLCO1B1—Metabolism—RRM2—urinary bladder cancer	1.66e-05	0.000274	CbGpPWpGaD
L-Carnitine—XDH—Metabolism—MTHFR—urinary bladder cancer	1.59e-05	0.000263	CbGpPWpGaD
L-Carnitine—SLCO1B1—Metabolism—HPGDS—urinary bladder cancer	1.54e-05	0.000254	CbGpPWpGaD
L-Carnitine—SLCO1B1—Metabolism—ENO2—urinary bladder cancer	1.54e-05	0.000254	CbGpPWpGaD
L-Carnitine—CPT1A—Metabolism—PTGS2—urinary bladder cancer	1.53e-05	0.000253	CbGpPWpGaD
L-Carnitine—SLCO1B1—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	1.53e-05	0.000252	CbGpPWpGaD
L-Carnitine—SLCO1B1—Metabolism—GSTT1—urinary bladder cancer	1.49e-05	0.000246	CbGpPWpGaD
L-Carnitine—SLCO1B1—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	1.47e-05	0.000242	CbGpPWpGaD
L-Carnitine—SLCO1B1—Transmembrane transport of small molecules—CREBBP—urinary bladder cancer	1.39e-05	0.00023	CbGpPWpGaD
L-Carnitine—CPT1A—Metabolism—PTEN—urinary bladder cancer	1.34e-05	0.000221	CbGpPWpGaD
L-Carnitine—XDH—Metabolism—PPARG—urinary bladder cancer	1.29e-05	0.000213	CbGpPWpGaD
L-Carnitine—CPT1A—Metabolism—EP300—urinary bladder cancer	1.28e-05	0.000211	CbGpPWpGaD
L-Carnitine—XDH—Metabolism—CREBBP—urinary bladder cancer	1.24e-05	0.000205	CbGpPWpGaD
L-Carnitine—SLCO1B1—Metabolism—NQO1—urinary bladder cancer	1.24e-05	0.000204	CbGpPWpGaD
L-Carnitine—SLCO1B1—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	1.2e-05	0.000198	CbGpPWpGaD
L-Carnitine—SLCO1B1—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	1.05e-05	0.000173	CbGpPWpGaD
L-Carnitine—SLCO1B1—Metabolism—GSTP1—urinary bladder cancer	1.03e-05	0.00017	CbGpPWpGaD
L-Carnitine—XDH—Metabolism—PTGS2—urinary bladder cancer	1.02e-05	0.000168	CbGpPWpGaD
L-Carnitine—SLCO1B1—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	9.99e-06	0.000165	CbGpPWpGaD
L-Carnitine—SLCO1B1—Metabolism—TYMS—urinary bladder cancer	9.59e-06	0.000159	CbGpPWpGaD
L-Carnitine—SLCO1B1—Metabolism—NCOR1—urinary bladder cancer	9.48e-06	0.000157	CbGpPWpGaD
L-Carnitine—SLCO1B1—Metabolism—GSTM1—urinary bladder cancer	9.48e-06	0.000157	CbGpPWpGaD
L-Carnitine—SLCO1B1—Metabolism—GPX1—urinary bladder cancer	9.08e-06	0.00015	CbGpPWpGaD
L-Carnitine—SLCO1B1—Metabolism—ERCC2—urinary bladder cancer	8.92e-06	0.000147	CbGpPWpGaD
L-Carnitine—XDH—Metabolism—PTEN—urinary bladder cancer	8.86e-06	0.000146	CbGpPWpGaD
L-Carnitine—XDH—Metabolism—EP300—urinary bladder cancer	8.45e-06	0.00014	CbGpPWpGaD
L-Carnitine—SLCO1B1—Metabolism—MTHFR—urinary bladder cancer	8.38e-06	0.000138	CbGpPWpGaD
L-Carnitine—SLCO1B1—Metabolism—PPARG—urinary bladder cancer	6.8e-06	0.000112	CbGpPWpGaD
L-Carnitine—SLCO1B1—Metabolism—CREBBP—urinary bladder cancer	6.53e-06	0.000108	CbGpPWpGaD
L-Carnitine—SLCO1B1—Metabolism—PTGS2—urinary bladder cancer	5.35e-06	8.83e-05	CbGpPWpGaD
L-Carnitine—SLCO1B1—Metabolism—PTEN—urinary bladder cancer	4.66e-06	7.7e-05	CbGpPWpGaD
L-Carnitine—SLCO1B1—Metabolism—EP300—urinary bladder cancer	4.45e-06	7.35e-05	CbGpPWpGaD
